基于CAB技术的新型Axl抗体偶联药物——BA3011

New Axl antibody drug conjugate based on CAB technology——BA3011

BA3011(CAB-AXL-ADC)是BioAtla公司开发的新型肿瘤微环境条件性激活的Axl受体靶向抗体偶联药物。其抗体部分通过条件性激活技术(conditionally active biologics,CAB)改造后,能选择性靶向于肿瘤组织的Axl受体。BA3011已获批进行Ⅰ/Ⅱ期临床试验,适应证包括非小细胞肺癌、去势抵抗性前列腺癌和胰腺癌等晚期实体瘤。BA3011是首个进入临床试验的CAB产品,标志着CAB由技术研发阶段跨入产品开发阶段。本文就Axl受体为靶标的药物,CAB技术和BA3011的临床进展情况作一概述。

BA3011（CAB-AXL-ADC） is a novel tumor microenvironment conditionally activated Axl receptortargeting antibody-drug conjugate developed by BioAtla Its antibody part was modified by conditionally active biologies（CAB）, which selectively acts on the Axl receptor in tumor tissues. BA3011 has been approved for Phase Ⅰ/Ⅱ clinical trials. The indications include advanced solid tumors. such as non-small cell lung cancer, castration-resistant prostate cancer, and pancreatic cancer. BA3011 is the first CAB product entering clinical trials, indicating CAB technology has matured. Drugs target of Axl receptor, CAB technology and clinical progress of BA3011 were reviewed in this article.